Michael Schafer, MD
Gastroenterology · Omaha, NENPI 1538240007
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,405 of the $30,109 with a category attached, or 71.1%. Boston Scientific accounts for 96.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $11,206 and has fallen 90.1% since, to $1,107 in 2025. Among gastroenterology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $246.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$29K
- Nestle Healthcare Nutrition Inc.$203
- Johnson & Johnson$163
- Sanofi$158
- AbbVie$143
- Pfizer$125
- plus $296 from 11 others
What the payments were for
- Speaking & faculty fees$21,40571%
- Travel & lodging$2,5268%
- Food & beverage$6,10520%
- Education$430%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 87 | $29,021 |
| Nestle Healthcare Nutrition Inc. | 2 | $203 |
| Johnson & Johnson | 3 | $163 |
| Sanofi | 2 | $158 |
| AbbVie | 9 | $143 |
| Pfizer | 1 | $125 |
| Gilead | 4 | $90 |
| AstraZeneca | 1 | $43 |
| Phathom Pharmaceuticals, Inc. | 5 | $32 |
| Covidien LP | 1 | $23 |
| Amgen | 1 | $18 |
| QOL Medical, LLC | 1 | $17 |
| Welch Allyn | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXALT Model D$14,473
- HABIB ENDOHPB$3,340
- ACQUIRE$3,240
- ORISE$461
- Resolution 360 Clip$352
- SPYGLASS$343
- GENERAL - THERAPIES$260
- EXALT$246
- AXIOS$216
- VOWST$190
- Apollo ESG NXT System$159
- OverStitch Endoscopic Suturing System$149
- Tremfya$139
- XELJANZ$125
- DUPIXENT$123
- GENERAL VASCULAR ACCESS$101
How this compares
$30,109 in reported general payments places this provider in the 90th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $81,739 |
| CreonLipase/Protease/Amylase | 37 | $61,234 |
| LialdaMesalamine | 11 | $14,206 |
| VoqueznaVonoprazan Fumarate | 13 | $8,286 |
| Mesalamine | 28 | $5,682 |
| Balsalazide Disodium | 25 | $4,543 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 159 | $3,299 |
| Ursodiol | 22 | $2,128 |
| Sucralfate | 17 | $1,981 |
| Pantoprazole Sodium | 160 | $1,738 |
| Omeprazole | 88 | $1,361 |
| Rabeprazole Sodium | 27 | $941 |
| Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg | 23 | $300 |
| Amitriptyline Hcl | 21 | $266 |
| Famotidine | 21 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $143 | $61,23437 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $32 | $8,28613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
- Trevor PearsonOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.